Pre-made Tadocizumab benchmark antibody ( Fab, anti-ITGA2B;ITGB3 therapeutic antibody, Anti-BDPLT16/BDPLT2/CD41/CD41B/GP2B/GPIIb/GT/GT1/GTA/HPA3/PPP1R93;BDPLT16/BDPLT2/BDPLT24/CD61/GP3A/GPIIIa/GT/GT2 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-made Tadocizumab benchmark antibody (Fab, anti-ITGA2B;ITGB3 therapeutic antibody, Anti-BDPLT16/BDPLT2/CD41/CD41B/GP2B/GPIIb/GT/GT1/GTA/HPA3/PPP1R93;BDPLT16/BDPLT2/BDPLT24/CD61/GP3A/GPIIIa/GT/GT2 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Tadocizumab is a humanized monoclonal antibody that acts on the cardiovascular system. It binds to integrin ¦ÁIIb¦Â3, a fibrinogen and fibronectin receptor found on platelets.
| Products Name (INN Index) | Pre-Made Tadocizumab biosimilar, Fab, Anti-ITGA2B;ITGB3 Antibody: Anti-BDPLT16/BDPLT2/CD41/CD41B/GP2B/GPIIb/GT/GT1/GTA/HPA3/PPP1R93;BDPLT16/BDPLT2/BDPLT24/CD61/GP3A/GPIIIa/GT/GT2 therapeutic antibody |
|---|---|
| INN Name | Tadocizumab |
| Target | ITGA2B_ITGB3 |
| Format | Fab |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2005 |
| Year Recommended | 2006 |
| Companies | PDL BioPharma,Yamanouchi |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | Coronary artery restenosis,Stroke,Thrombosis |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | ITGA2B_ITGB3 |
| Package |
